Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects

NCT04228302 · View on ClinicalTrials.gov ↗

Study Summary

This is a first-in-human study with EC5026, a new drug candidate intended to treat neuropathic pain. The purpose of the study is to provide initial safety, tolerability, and pharmacokinetics data of single ascending oral doses of EC5026 in healthy subjects.

Conditions Studied

Interventions

  • DRUG EC5026 oral capsule
  • OTHER Placebo oral capsule

Study Locations (1)

Texas

  • PPD Phase I Clinic — Austin

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2019-12-09
Est. Completion 2020-07-07
Phase Phase 1

Sponsor

EicOsis Human Health

35 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04228302

The ClinicalTrials.gov registry entry for NCT04228302 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EicOsis Human Health, which has 35 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 2 interventions — of which EC5026 oral capsule is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04228302 reports 1 study location spanning 1 distinct geographic area — top geographies include Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04228302 about?

NCT04228302 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects". This is a first-in-human study with EC5026, a new drug candidate intended to treat neuropathic pain. The purpose of the study is to provide initial safety, tolerability, and pharmacokinetics data of single ascending oral doses of EC5026 in healthy subjects.

What is the current status of trial NCT04228302?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-12-09. Estimated completion is 2020-07-07.

What conditions does trial NCT04228302 study?

This clinical trial studies the following conditions: Healthy Adults. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04228302?

The interventions under investigation include: EC5026 oral capsule (DRUG), Placebo oral capsule (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04228302?

This trial is sponsored by EicOsis Human Health, which has 35 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04228302 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial